Search Result
Results for "
anti-cancer
" in MedChemExpress (MCE) Product Catalog:
3950
Inhibitors & Agonists
46
Biochemical Assay Reagents
92
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-114002
-
|
Others
|
Cancer
|
Anticancer agent 129 (Compound 3a), a quinoline derivative, predicting to has anti-cancer activity .
|
-
-
- HY-156187
-
|
Others
|
Cancer
|
Anticancer agent 161 (Compound 3b) is a bioactive alkynol with anti-cancer potential. Anticancer agent 161 can trigger autophagy and mitochondrial membrane potential depletion .
|
-
-
- HY-W548095
-
|
Drug Derivative
|
Cancer
|
Anticancer agent 170 (compound 3a) is a ketone derivative, and shows potency anti-cancer activity against A549, with the IC50 of 6.62 μM .
|
-
-
- HY-147781
-
|
Apoptosis
|
Cancer
|
Anticancer agent 66 (Compound 13e) is an anti-cancer agent. Anticancer agent 66 induces apoptosis and increases sub-G1 cell population in MCF-7 cells. Anticancer agent 66 is a ciprofloxacin analog .
|
-
-
- HY-147782
-
|
Apoptosis
|
Cancer
|
Anticancer agent 67 (Compound 13g) is an anti-cancer agent. Anticancer agent 67 induces apoptosis and increases sub-G1 cell population in MCF-7 cells. Anticancer agent 67 is a ciprofloxacin analog .
|
-
-
- HY-147783
-
|
MDM-2/p53
|
Cancer
|
Anticancer agent 68 is (Compound 12) is an anti-cancer agent. Anticancer agent 68 arrests the cells at the G2/M phase and induces programmed cell death. Anticancer agent 68 induces upregulation of tumor suppression via activation of p53 & PTEN .
|
-
-
- HY-128689
-
|
Others
|
Cancer
|
Anticancer agent 3 (Compound 4) is a anti-cancer agent .
|
-
-
- HY-149215
-
|
Others
|
Cancer
|
Anticancer agent 101 is a derivative of tetracaine. Anticancer agent 101 has anti-cancer activity .
|
-
-
- HY-149062
-
|
Apoptosis
|
Cancer
|
Anticancer agent 102 is a derivative of tetracaine. Anticancer agent 102 has anti-cancer activity. Anticancer agent 102 induces apoptosis .
|
-
-
- HY-149214
-
|
Others
|
Cancer
|
Anticancer agent 100 is a derivative of tetracaine with anti-cancer activity and can be used in cancer research .
|
-
-
- HY-162285
-
|
Akt
|
Cancer
|
Anticancer agent 189 (compound 4) is an anticancer agent that antagonizes CRC effects by targeting AKT1 .
|
-
-
- HY-154799
-
|
Others
|
Cancer
|
Anticancer agent 112 is a potent anti-cancer agent for cancer research, extracted from patent WO2020198567 .
|
-
-
- HY-162276
-
|
Reactive Oxygen Species
DNA/RNA Synthesis
|
Cancer
|
Anticancer agent 188 (compound D43) inhibits DNA synthesis in TNBC cells, leading to cell cycle arrest at the G2/M phase. Anticancer agent 188 has anti-cancer viability by inducing ROS-mediated apoptosis and DNA damage .
|
-
-
- HY-149344
-
|
Apoptosis
Autophagy
EGFR
|
Cancer
|
Anticancer agent 133 (compound Rh2) is an anti-cancer agent with cytotoxic and antimetastatic activities. Anticancer agent 133 induces cell cycle arrest, apoptosis, and autophagy. Anticancer agent 133 also inhibits cell metastasis via suppression of EGFR expression mediated by FAK-regulated integrin β1 .
|
-
-
- HY-146444
-
|
Apoptosis
Bcl-2 Family
Caspase
Reactive Oxygen Species
|
Cancer
|
Anticancer agent 56 (compound 4d) is a potent anti-cancer agent with agent-likeness properties, possessing anticancer activity against several cancer cell lines (IC50<3 μM). Anticancer agent 56 induces cell cycle arrest at G2/M phase and triggers mitochondrial apoptosis pathway. Anticancer agent 56 acts by accumulation of ROS, up regulation of BAX, down regulation of Bcl-2 and activation of caspases 3, 7, 9 .
|
-
-
- HY-116904
-
|
Apoptosis
Akt
|
Cancer
|
Anticancer agent 253 (Compound 26) has anti-cancer activity against breast cancer cells, with IC50s of 6 μM (MCF-7), 10 μM (MDA-MB-231) and 6.4 μM (4T1 cells). Anticancer agent 253 arrests cell cycle and induces mitochondria-mediated apoptosis in cancer cells. Anticancer agent 253 inhibits Akt phosphorylation in human breast and prostate cancer .
|
-
-
- HY-149092
-
|
TAM Receptor
|
Cancer
|
Anticancer agent 109 (compound 6-15) is an inhibitor of the Gas6-Axl axis with anti-cancer activity. Anticancer agent 109 inhibits the expression of Gas6 and Axl, and the expression p-PI3K and p-AKT in cancer cells, leads to G1 phase arrest and promotes cancer cells apoptosis, and inhibits tumor growth significantly in nude mouse tumor bearing models .
|
-
-
- HY-123715
-
|
Others
|
Cancer
|
Anticancer agent 255 is a monocarbonylated curcumin-1,2,3-oxazole conjugate with significant anticancer activity. The IC50 values of Anticancer agent 255 in prostate cancer cells PC-3 and DU-145 are 8.8μM and 9.5μM respectively. The IC50 values of Anticancer agent 255 against breast cancer cells MCF-7, MDA-MB-231 and 4T1 are 6μM, 10μM and 6.4μM, showing good anti-cancer activity Effect. Anticancer agent 255 can induce mitochondria-mediated apoptosis in cancer cells and prevent cell cycle progression. Anticancer agent 255 down-regulated the cell proliferation marker PCNA and inhibited the activation of cell survival proteins. Anticancer agent 255 up-regulated the pro-apoptotic protein Bax and down-regulated the anti-apoptotic protein Bcl-2 .
|
-
-
- HY-146406
-
|
Apoptosis
|
Cancer
|
Anticancer agent 52 is a potent anticancer agent. Anticancer agent 52 shows in vitro cytotoxicity. Anticancer agent 52 induces apoptosis. Anticancer agent 52 shows antitumor effect. Anticancer agent 52 has the potential for the research of bladder cancer .
|
-
-
- HY-146396
-
|
MetAP
|
Cancer
|
Anticancer agent 51 (compound 3d) is a potent anticancer agent with an Ki of 731.62 nM. Anticancer agent 51 shows anticancer activity. Anticancer agent 51 has the potential for the research of prostate cancer .
|
-
-
- HY-143303
-
|
Apoptosis
|
Cancer
|
Anticancer agent 32 (compound 2g) is an anticancer agent. Anticancer agent 32 shows anticancer activities, affects cell cycle and induces cell apoptosis. Anticancer agent 32 can be used for the research of cancer .
|
-
-
- HY-162392
-
|
Others
|
Cancer
|
Anticancer agent 203 (compound 27) is an anticancer agent. Anticancer agent 203 shows cytotoxicity. Anticancer agent 203 has the potential for the research of hepatoma .
|
-
-
- HY-146433
-
|
Apoptosis
|
Cancer
|
Anticancer agent 55 is a potent anticancer agent. Anticancer agent 55 shows anticancer activity via reducing the cell viability and cell migration in a dose-dependent manner. Anticancer agent 55 induces apoptosis. Anticancer agent 55 has the potential for the research of prostate cancer and breast cancer .
|
-
-
- HY-146357
-
|
Microtubule/Tubulin
|
Cancer
|
Anticancer agent 48 (compound 48) is a broad spectrum anticancer agent. Anticancer agent 48 inhibits tubulin polymerization. Anticancer agent 48 shows antiproliferative activity. Anticancer agent 48 shows antitumor activity in vivo. Anticancer agent 48 has the potential for the research of solid and hematological tumors .
|
-
-
- HY-146358
-
|
Microtubule/Tubulin
|
Cancer
|
Anticancer agent 49 (compound 69) is a broad spectrum anticancer agent. Anticancer agent 49 inhibits tubulin polymerization. Anticancer agent 49 shows antiproliferative activity. Anticancer agent 49 has the potential for the research of solid and hematological tumors .
|
-
-
- HY-146063
-
|
Apoptosis
|
Cancer
|
Anticancer agent 54 is a potent anticancer agent. Anticancer agent 54 shows antiproliferative activity. Anticancer agent 54 induces apoptosis and cell cycle arrest at G0/G1 phases. Anticancer agent 54 shows anticancer activity depends on DNA intercalation and ROS generation .
|
-
-
- HY-151119
-
|
Cytochrome P450
|
Cancer
|
Anticancer agent 78 is a potent anticancer agent. Anticancer agent 78 shows cytotoxicity. Anticancer agent 78 exhibits anti-aromatase activity with an IC50 value of 0.9 µM. Anticancer agent 78 has the potential for the research of breast cancer .
|
-
-
- HY-163558
-
|
Others
|
Cancer
|
Anticancer agent 212 (compound 10a) is a potent anticancer agent. Anticancer agent 212 shows cytotoxicity [1]
|
-
-
- HY-146286
-
|
Apoptosis
|
Cancer
|
Anticancer agent 44 (compound 2a) is a potent anticancer agent. Anticancer agent 44 shows cytotoxicity activity in cancer cells. Anticancer agent 44 induces apoptosis. Anticancer agent 44 shows low toxicity towards activated lymphocytes of human blood .
|
-
-
- HY-146548
-
|
Apoptosis
Bcl-2 Family
Caspase
PARP
|
Cancer
|
Anticancer Agent 43 is a potent anticancer agent. Anticancer Agent 43 induces apoptosis by caspase 3, PARP1, and Bax dependent mechanisms. Anticancer Agent 43 induces DNA damage .
|
-
-
- HY-163619
-
|
Apoptosis
Mitophagy
|
Cancer
|
Anticancer agent 227 (compound YNU-1c) is a potent anticancer agent. Anticancer agent 227 shows antiproliferative activity. Anticancer agent 227 induces apoptosis and mitophagy .
|
-
-
- HY-146290
-
|
Apoptosis
|
Cancer
|
Anticancer agent 46 (compound 2b) is a potent and selective anticancer agent. Anticancer agent 46 shows cytotoxicity activity in cancer cells. Anticancer agent 46 induces apoptosis. Anticancer agent 46 shows low toxicity towards activated lymphocytes of human blood .
|
-
-
- HY-151471
-
|
c-Myc
|
Cancer
|
Anticancer agent 84 is an anticancer agent. Anticancer agent 84 represses the transcription of c-MYC by stabilizing the G-quadruplex (G4) structure. Anticancer agent 84 can be used for the research of cancer .
|
-
-
- HY-146407
-
|
Apoptosis
|
Cancer
|
Anticancer agent 53 is a potent anticancer agent. Anticancer agent 53 shows in vitro cytotoxicity. Anticancer agent 53 induces apoptosis and cell cycle arrest in S/G2/M phases. Anticancer agent 53 shows antitumor activity with no apparent toxicity .
|
-
-
- HY-149805
-
|
Apoptosis
|
Cancer
|
Anticancer agent 110 is an anticancer agent with in vitro anticancer activity and excellent anti-leukemia potency. Anticancer agent 110 is highly cytotoxic to K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. Anticancer agent 110 causes DNA damage and leads to apoptosis .
|
-
-
- HY-163515
-
|
Ras
|
Cancer
|
Anticancer agent 207 (compound 10b) is a potent anticancer agent. Anticancer agent 207 bounds to the NRAS rG4 with a KD value of 2.31 µM. Anticancer agent 207 shows cytotoxicity and decreases the expression of NRAS protein. Anticancer agent 207 shows antitumor activity .
|
-
-
- HY-151570
-
|
Others
|
Cancer
|
Anticancer agent 87 is a potent anticancer agent. Anticancer agent 87 can be used in the research of breast adenocarcinoma and liver cancer .
|
-
-
- HY-151572
-
|
Others
|
Cancer
|
Anticancer agent 88 is a potent anticancer agent. Anticancer agent 88 can be used in the research of breast adenocarcinoma and liver cancer .
|
-
-
- HY-154800
-
|
Others
|
Cancer
|
Anticancer agent 113 is a compound with anticancer activity .
|
-
-
- HY-155570
-
|
PI3K
Apoptosis
Caspase
PARP
|
Cancer
|
Anticancer agent 137 (8q) is a potent PI3k inhibitor. Anticancer agent 137 has broad-spectrum anticancer activity. Anticancer agent 137 induces G2/M cell cycle arrest and apoptosis. Anticancer agent 137 increases cleaved PARP, caspase 3, and 7. Anticancer agent 137 can be used in research of cancer .
|
-
-
- HY-158407
-
|
Apoptosis
|
Cancer
|
Anticancer agent 220 is a chromanone derivative with anticancer effects. Anticancer agent 220 shows highly potent activity in the colon cancer cell lines. Anticancer agent 220 induces apoptosis and cell cycle arrest in cells .
|
-
-
- HY-147968
-
|
Others
|
Cancer
|
Anticancer agent 74 is a moderate anticancer agent. Anticancer agent 74 has lower selectivity and cytotoxicity than doxorubicin to normal cell .
|
-
-
- HY-154865
-
|
Lactate Dehydrogenase
|
Cancer
|
Anticancer agent 121, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research .
|
-
-
- HY-154866
-
|
Lactate Dehydrogenase
|
Cancer
|
Anticancer agent 122, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research .
|
-
-
- HY-76665
-
|
Others
|
Cancer
|
Anticancer agent 209 (compound 1) is an anticancer agent. Anticancer agent 209 exhibits cytotoxic activity against colon cancer in vitro .
|
-
-
- HY-N12142
-
|
Others
|
Cancer
|
Anticancer agent 156 (compound 11) is a powerful anticancer agent based on Miliusanes (anticancer lead molecule). Anticancer agent 156 effectively inhibits the growth of human cancer cells and shows significant cytotoxicity to gastric cancer cells .
|
-
-
- HY-163808
-
|
Apoptosis
|
Cancer
|
Anticancer agent 237 (compound 13) is a potent anticancer agent. Anticancer agent 237 shows cytotoxicity. Anticancer agent 237 induces apoptosis and cell cycle arrest at the S and G2/M phases .
|
-
-
- HY-146040
-
|
Apoptosis
|
Cancer
|
Anticancer agent 47 (compound 4j) is a potent anticancer agent. Anticancer agent 47 shows antiproliferative activities. Anticancer agent 47 induces apoptosis and cell cycle arrest at G0/G1 phase. Anticancer agent 47 shows shows antitumor activities in vivo .
|
-
-
- HY-147971
-
|
Parasite
Topoisomerase
|
Infection
Cancer
|
Anticancer agent 75 is a potent anticancer agent. Anticancer agent 75 shows cytotoxicity and selectivity in cancer cell lines. Anticancer agent 75 shows cytotoxicity to normal human kidney cell lines is at least 35 times lower than that of the Doxorubicin standard. Anticancer agent 75 shows good activity of antiplasmodial .
|
-
-
- HY-162389
-
|
Others
|
Cancer
|
Anticancer agent 202 (compound 3) is a Anticancer agent .
|
-
- HY-146030
-
|
Others
|
Cancer
|
Anticancer agent 46 (compound 2) is a potent anticancer agent. Anticancer agent 46 shows antiproliferative activity with an IC50 of 0.986 µM for MGC803 cells. Anticancer agent 46 has the potential for the research of gastric cancer .
|
-
- HY-157047
-
|
Others
|
Cancer
|
Anticancer agent 171 (Compound 6a) is an oxime analogue. Anticancer agent 171 has anticancer activity against HCT116 cells with an IC50 value of 3.43 μM. Anticancer agent 171 can be used for the research of cancer .
|
-
- HY-163076
-
|
Apoptosis
|
Others
|
Anticancer agent 174 (BA-3) is an anticancer agent. Anticancer agent 174 induces tumor cell apoptosis through the mitochondrial pathway. Anticancer agent 174 inhibits cancer cell proliferation in melanoma mouse xenograft model .
|
-
- HY-149977
-
|
Cytochrome P450
|
Cancer
|
Anticancer agent 111 (compound 11) is a potent cytochrome P450 inhibitor with an IC50 value of 3 μM for CYP3A4. Anticancer agent 111 has anticancer activity. Anticancer agent 111 can be used in research of cancer .
|
-
- HY-128498
-
|
Others
|
Cancer
|
Anticancer agent 182 (Compound 1) is a cytotoxic flavonoid compound isolated from the root ofMuntingia colabura L. Anticancer agent 182 exhibits anticancer activity .
|
-
- HY-139711
-
|
Others
|
Cancer
|
Anticancer agent 13 is an anticancer agent from dicarboxylic acids and amines.
|
-
- HY-78884
-
|
Amino Acid Derivatives
|
Cancer
|
Anticancer agent 9, a glycine derivative, is an anticancer agent. Anticancer agent 9 can inhibit tumor cells viability of myelogenous leukemia and human prostate cancer .
|
-
- HY-155278
-
|
Others
|
Cancer
|
Anticancer agent 162 (compound 1d) is an effective anticancer theranostic agent. Anticancer agent 162 induces oncosis of Hela cells with lipophilicity and cytotoxicity selectivity .
|
-
- HY-163153
-
|
Apoptosis
|
Cancer
|
Anticancer agent 184 (Compound 6o) is a novel, effective and low toxic anticancer drug. Anticancer agent 184 induces apoptosis by blocking the S phase .
|
-
- HY-147514
-
|
Apoptosis
Caspase
PARP
Bcl-2 Family
|
Cancer
|
Anticancer agent 64 (compound 5m) shows cytotoxic activity in CCRF-CEM cells, with IC50 of 2.4 μM. Anticancer agent 64 shows good anticancer activity through apoptosis induction. Anticancer agent 64 induces caspase 3 and 7 activation and PARP cleavage. Anticancer agent 64 induces significant effect of mitochondria depolarization .
|
-
- HY-149216
-
|
Others
|
Cancer
|
Anticancer agent 103 (Compound 2k) is a potent anticancer agent .
|
-
- HY-148906
-
-
- HY-158391
-
|
Topoisomerase
|
Cancer
|
Anticancer agent 218 (P136) is a Camptothecin compound, with anticancer activity .
|
-
- HY-158392
-
|
Topoisomerase
|
Cancer
|
Anticancer agent 219 (P139) is a Camptothecin compound, with anticancer activity .
|
-
- HY-115962
-
|
Others
|
Cancer
|
Anticancer agent 37 (compound 18), a sulfonylurea derivative, is a potent anticancer agent. Anticancer agent 37 inhibits HePG2 cell growth with an IC50 of 17.2 µg/mL .
|
-
- HY-115963
-
|
Others
|
Cancer
|
Anticancer agent 38 (compound 19), a sulfonylurea derivative, is a potent anticancer agent. Anticancer agent 38 inhibits A431 cell growth with an IC50 of 5.2 µg/mL .
|
-
- HY-149231
-
|
Apoptosis
|
Cancer
|
Anticancer agent 104 has anticancer activity, and induces cancer cell apoptosis .
|
-
- HY-155087
-
|
Parasite
|
Infection
Cancer
|
Anticancer agent 140 (Compd 3) is a compound with potential anticancer and antiparasitic activities .
|
-
- HY-146516
-
|
MDM-2/p53
Apoptosis
Reactive Oxygen Species
|
Cancer
|
Anticancer agent 42 (compound 10d) is an orally active anticancer agent, and shows a potent antitumor activity against MDA-MB-231 cell with an IC50 of 0.07 μM. Anticancer agent 42 can exert its anticancer activity by activating apoptotic pathway and p53 expression. Anticancer agent 42 can be used to study metastatic breast cancer .
|
-
- HY-149949
-
|
Apoptosis
|
Cancer
|
Anticancer agent 105 is a compound based on thienopyrimidine scaffold, with with good safety and anticancer properties. Anticancer agent 105 shows selective toxicity towards melanoma cancer, and induces apoptosis. And Anticancer agent 105 significantly inhibits the metastatic nodules, even in pulmonary metastatic melanoma mouse model .
|
-
- HY-162046
-
|
Necroptosis
Ferroptosis
|
Cancer
|
Anticancer agent 178 (compound C2) is a potent anticancer agent. Anticancer agent 178 inhibits MDA-MB 231 cells proliferation and metabolic activity with IC50s of 1.1 and 4.2 μM. Anticancer agent 178 induces ferroptosis and necroptosis in cells .
|
-
- HY-163089
-
|
Others
|
Cancer
|
Anticancer agent 176 (Compoint 10α) is an anticancer agent. Anticancer agent 176 exhibits excellent in vitro cytotoxic activity against neuroblastoma with an IC50 value of 6.3 μM .
|
-
- HY-154861
-
|
Bacterial
Apoptosis
Necroptosis
|
Cancer
|
Anticancer agent 118, a N‑acylated ciprofloxacin derivative, has anti-bacterial and anticancer activities. Anticancer agent 118 shows high activity against Gram-positive strains and antiproliferative activities against prostate PC3 cells. Anticancer agent 118 can be used for antitumor research .
|
-
- HY-151121
-
|
Others
|
Cancer
|
Anticancer agent 80 (Compound 3c) is an anticancer agent. Anticancer agent 80 exhibits the dark cytotoxicity against T47-D with IC50 of 10.14 µM .
|
-
- HY-143302
-
|
Apoptosis
|
Cancer
|
Anticancer agent 31 is a 1,3-diphenylurea quinoxaline derivative, and a anticancer agent. Anticancer agent 31 exhibits antitumor acitvity by arresting cell cycle at S phase and inducing apoptosis .
|
-
- HY-162456
-
|
Apoptosis
Reactive Oxygen Species
|
Cancer
|
Anticancer agent 205 (compound 9) is a potent anticancer agent. Anticancer agent 205 binds to G4-mtDNA target and inhibits the replication, transcription, and translation of mtDNA (mitochondrial genome). Anticancer agent 205 causes mitochondrial dysfunction, increases ROS production, induces DNA damage and cellular senescence. Anticancer agent 205 induces apoptosis and cell cycle arrests at G0/G1 phase. Anticancer agent 205 has the potential for the research of colorectal cancer .
|
-
- HY-158373
-
|
Autophagy
|
Cancer
|
Anticancer agent 213 (Compound 1) exhibits anticancer efficacy by self-assembling into micelles, depleting membran cholesterol and thus inhibiting cancer cells. Anticancer agent 213 exhibits cytotoxicity against HeLa and PC3, with IC50 of 10.3 and 13.7 μM. Anticancer agent 213 induces autophagy .
|
-
- HY-151564
-
|
Others
|
Cancer
|
Anticancer agent 85 (compound 6j) is an anticancer agent that shows good cytotoxicity against MCF7 cells. Anticancer agent 85 can be used in breast cancer and other cancer studies .
|
-
- HY-139635
-
-
- HY-151888
-
|
Others
|
Cancer
|
Anticancer agent 92 (Compound 5f) is an anticancer agent that is nontoxic against noncancerous cells .
|
-
- HY-162379
-
|
Others
|
Cancer
|
Anticancer agent 200 (6d) is a potential noncovalent anticancer inhibitor and an anti-metastatic agent .
|
-
- HY-146389
-
|
MDM-2/p53
P-glycoprotein
|
Cancer
|
Anticancer agent 50 (compound 6) is a potent ABCB1 efflux pump modulator. Anticancer agent 50 shows cytotoxic effects and antiproliferative effects. Anticancer agent 50 decreases the expression of cyclin D1 and induces p53 expression. Anticancer agent 50 has the potential for the research of T-lymphoma .
|
-
- HY-162079
-
|
MMP
Apoptosis
|
Cancer
|
Anticancer agent 183 (compound 4h) inhibits the matrix metalloproteinase-9 (MMP-9) viability than 75% at 100 μg/mL. Anticancer agent 183 has anticancer activity with an IC50 value of <0.14 μM on the A549 cell line. Anticancer agent 183 induces apoptotic .
|
-
- HY-149873
-
|
Histone Methyltransferase
|
Cancer
|
Anticancer agent 126 (compound 12) is a WDR5 inhibitor with anticancer effects. Anticancer agent 126 disrupts WDR5-MYC interaction in cells and reduce MYC target gene expression .
|
-
- HY-155167
-
|
Antibiotic
Fungal
|
Cancer
|
Anticancer agent 151 (compound 6C) is an anticancer agent. Anticancer agent 151 exhibits excellent in vitro cytotoxic activity against MCF-7 cells with an IC50 value of 6.3 μM .
|
-
- HY-158025
-
|
DNA/RNA Synthesis
|
Cancer
|
Anticancer agent 198 (compound 18b) is a potent anticancer agent and potential WRN protein inhibitor. Anticancer agent 198 was significantly toxic to K562 cells and WRN-overexpressing PC3 cells .
|
-
- HY-149950
-
|
Apoptosis
|
Cancer
|
Anticancer agent 106 (compound 10ic) is an anticancer agent that induces apoptosis in B16-F10 melanoma cells. Anticancer agent 106 also potently inhibits metastatic nodules in a mouse model of lung metastatic melanoma. Anticancer agent 106 can be used in the study of cancer, especially lung metastatic melanoma .
|
-
- HY-169907
-
|
Orphan Receptor
|
Neurological Disease
Metabolic Disease
Cancer
|
Anticancer agent 258 is an imidazo [1,2-B][1,2,4] triazol derivative. Anticancer agent 258 regulates the activity of nuclear receptors. Anticancer agent 258 has an EC50 of 63 nM against Nurr in N2A cells. Anticancer agent 258 has IC50 of 0.1 pM for Nur77in HEK293 cells. Anticancer agent 258 can be used in the study of cancer, metabolic diseases and neurological disorders .
|
-
- HY-155964
-
|
Apoptosis
|
Cancer
|
Anticancer agent 153 (Compound 3) induces apoptosis by Reactive Oxygen Species generation. Anticancer agent 153 increases the loss of mitochondrial membrane potential (MMP) levels. Anticancer agent 153 inhibits cancer cell proliferation .
|
-
- HY-162481
-
|
Apoptosis
|
Cancer
|
Anticancer agent 210 (Compound 7a) is a Gefitinib (HY-50895) derivative. Anticancer agent 210 inhibits proliferation, migration and colony formation of cancer cells. Anticancer agent 210 induces apoptosis in cells H1299 .
|
-
- HY-N11572
-
|
Others
|
Cancer
|
Anticancer agent 96 (Compound 4) is an anticancer agent that shows cytotoxic activities against human cancer cells .
|
-
- HY-160871
-
|
Others
|
Cancer
|
Anticancer agent 208 (C014) is an anticancer agent that can be used to inhibit cancer or prevent its recurrence .
|
-
- HY-146467
-
|
Drug Derivative
|
Cancer
|
Anticancer agent 62 (compound 4c) is a potent anticancer agent. Anticancer agent 62 shows antiproliferative activity in HepG2, Bel-7402 and MCF-7 cancer cells, with IC50 values of 0.019, 0.060 and 0.016 μM, respectively. Anticancer agent 62 shows effective tumor growth inhibition .
|
-
- HY-144808
-
|
Others
|
Cancer
|
Anticancer agent 40 (compound 3e) is a potent anticancer agent. Anticancer agent 40 shows anticancer activities with IC50s of 0.94, 0.98, 0.96, 0.95, 2.13 nM for SKBR-3, SKOV-3, PC-3, U-87, HDF cells, respectively .
|
-
- HY-147906
-
|
Apoptosis
PARP
|
Cancer
|
Anticancer agent 71 (Compound 4b) is a potent anticancer agent and induces apoptosis. Anticancer agent 71 arrests cell cycle at G2/M phase and induces apoptosis through upregulating Bax, Ikb-α and cleaved PARP and downregulating Bcl-2 expression levels. Anticancer agent 71 shows antiproliferative activity .
|
-
- HY-147918
-
|
DNA/RNA Synthesis
|
Cancer
|
Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo .
|
-
- HY-155018
-
|
IAP
|
Cancer
|
Anticancer agent 127 (142D6) is an IAP inhibitor that covalently targets the BIR3 domains of XIAP, cIAP1, and cIAP2. Anticancer agent 127 targets the BIR3 domains of XIAP, cIAP1, and cIAP2 with IC50s of 12 nM, 14 nM, and 9 nM, respectively. Anticancer agent 127 has anticancer effects .
|
-
- HY-150571
-
|
Topoisomerase
c-Myc
Apoptosis
ROS Kinase
|
Cancer
|
Anticancer agent 76 (Compound CT2-3) is an anticancer agent. Anticancer agent 76 significantly inhibits the proliferation of human NSCLC cells, induces cell cycle arrest, causes ROS generation and induces cell apoptosis .
|
-
- HY-149061
-
|
Apoptosis
|
Cancer
|
Anticancer agent 99 (compound 2p) has good anticancer activity against HepG2 cells, with an IC50 value of 35.9 μM. Anticancer agent 99 can induce apoptosis and has anti-proliferation effect .
|
-
- HY-163616
-
|
Apoptosis
|
Cancer
|
Anticancer agent 221 (Compound 4h) is an orally active anticancer agent and an antioxidant agent. Anticancer agent 221 exhibits cytotoxicity to cancer cells A549 (IC50=22.09 µg/mL) and MCF-7 (IC50=6.40 µg/mL), and induces apoptosis. Anticancer agent 221 exhibits antioxidant efficacy with an IC50 of 42.46 μM in DPPH experiment. Anticancer agent 221 exhibits antitumor efficacy against breast cancer in mouse models .
|
-
- HY-147909
-
-
- HY-149890
-
|
Apoptosis
|
Cancer
|
Anticancer agent 130 (compound 8d) is an anticancer agent that can significantly induce apoptosis in A549 cells .
|
-
- HY-157048
-
|
Others
|
Cancer
|
Anticancer agent 172 (8d) possesses anticancer activity, with an IC50 of 6.96 μM in HCT116 cells .
|
-
- HY-162239
-
|
Others
|
Cancer
|
Anticancer agent 187 (Compound 4) is an anticancer agent that can target sarcoma cells in tumor-bearing mouse models. Anticancer agent 187 exhibits cytotoxic activity against HepG2, Caco2, and MCF-7 cells .
|
-
- HY-146466
-
|
Others
|
Cancer
|
Anticancer agent 61 (compound 3v) is an orally active and potent anticancer agent. Anticancer agent 61 shows antiproliferative activity in HepG2, Bel-7402 and MCF-7 cancer cells, with IC50 values of 1.12, 1.97 and 1.08 μM, respectively. Anticancer agent 61 shows effective tumor growth inhibition .
|
-
- HY-N11919
-
|
Others
|
Cancer
|
Anticancer agent 149 (compound 3) is an anticancer agent isolated from the rhizome of Dioscorea dioscorea (DM). Anticancer agent 149 exhibits selective cytotoxic activity against MCF-7 cells (IC50=31.41 μM) .
|
-
- HY-151092
-
|
Apoptosis
|
Cancer
|
Anticancer agent 77 (Compound 6c) shows anticancer activity, and can be widely used in synthesis and medicinal chemistry research .
|
-
- HY-155339
-
|
Apoptosis
DNA/RNA Synthesis
|
Cancer
|
Anticancer agent 168 (compound d16) is a inhibitor of DNA2. Anticancer agent 168 induces apoptosis and cell-cycle arrest mainly at S-phase, and exhibits anticancer activities and overcomes chemotherapy resistance in mutp53-bearing cancers .
|
-
- HY-162453
-
|
Apoptosis
MMP
|
Cancer
|
Anticancer agent 204 (Compound 6), a cinnamide fluorinated derivative, possesses anticancer activity. Anticancer agent 204 can arrest the cell cycle of HepG2 cells in the G1 phase and induce apoptosis by reducing the level of mitochondrial membrane polarization (MMP) .
|
-
- HY-149388
-
|
Microtubule/Tubulin
|
Cancer
|
Anticancer agent 139 (Compound 6h) has potent anticancer activity. Anticancer agent 139 displayed a π–cationic interaction with the residue Lys352 of Tublin. Anticancer agent 139 has good anticancer activity against SNB-19, OVCAR-8, and NCI-H40 with PGIs of 86.61, 85.26, and 75.99, respectively. Anticancer agent 139 also has moderate anticancer activity against HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 with PGIs of 67.55, 65.46, 59.09, 59.02, 57.88, 56.88, 56.53, 56.4, and 51.88 respectively .
|
-
- HY-156253
-
|
Others
|
Cancer
|
Anticancer agent 166 (compound 3) is an anticancer agent with an excellent inhibition activity against Caco-2 (IC50 = 9.6 nM) .
|
-
- HY-151426
-
|
Apoptosis
|
Cancer
|
Anticancer agent 83 is a potent anticancer agent, inhibits LOX IMVI cells growth with a GI50 value of 0.15 mM. Anticancer agent 83 reduces mitochondrial membrane potential and induces DNA damage to induces leukemia cells apoptosis .
|
-
- HY-149832
-
|
Proteasome
|
Cancer
|
Anticancer agent 114 is a potent and orally active dipeptide boronic acid ester proteasome inhibitor with an IC50 value of 2.2 nM. Anticancer agent 114 has antiproliferative activity against the RPMI-8226 cells. Anticancer agent 114 can be used in research of multiple myeloma .
|
-
- HY-161648
-
|
Drug Derivative
|
Cancer
|
Anticancer agent 222 (Compound 19) is an orally active anticancer agent that exhibits significant anticancer activity against Huh7, FOCUS, SNU475, SNU182, HepG2, and Hep3B cells (IC50 = 2.9–9.3 μM) .
|
-
- HY-115959
-
|
Bacterial
|
Inflammation/Immunology
Cancer
|
Anticancer agent 34 (compound 9), a sulfonylurea derivative, is a potent antimicrobial and anticancer agent. Anticancer agent 34 inhibits the microbial growth of B. mycoides, E. coli, and C. albicans with a MIC between 0.156 and 0.039 mg/ml. Anticancer agent 34 inhibits A549, PC3 cell growth with IC50s of 8.4 µg/ml, 7.8 µg/ml, respectively .
|
-
- HY-115961
-
|
Bacterial
|
Inflammation/Immunology
Cancer
|
Anticancer agent 36 (compound 11), a sulfonylurea derivative, is a potent antimicrobial and anticancer agent. Anticancer agent 36 inhibits the microbial growth of B. mycoides, E. coli, and C. albicans with a MIC between 0.156 and 0.039 mg/L. Anticancer agent 36 inhibits A549, PC3 cell growth with IC50s of 19.7 µg/mL, 11.9 µg/mL, respectively .
|
-
- HY-147816
-
|
Mitochondrial Metabolism
|
Cancer
|
Anticancer agent 70 (Compound 21), an anticancer agent, exhibits remarkable cytotoxic activity against numerous human cancer cell lines. Anticancer agent 70 results in the G0/G1-cell cycle arrest with a concomitant increase in p53 and p21 protein levels. Anticancer agent 70 leads to ATP depletion and disruption of the mitochondrial membrane potential .
|
-
- HY-122185
-
|
Apoptosis
Microtubule/Tubulin
|
Cancer
|
Anticancer agent 211 (AK301) can inhibit tubulin polymerization. Anticancer agent 211 can block the division of human colon cancer cells. Anticancer agent 211 can increase the sensitivity of human colon cancer cells to apoptotic ligands and promote cell apoptosis .
|
-
- HY-164064
-
|
ClpP
|
Cancer
|
Anticancer agent 230 (example 65) is a caseinolytic protease P (ClpP) activator with anticancer activity. Anticancer agent 230 is able to induce the degradation of mitochondrial proteins in SUM159 and MDA-MB-231 triple-negative breast cancer cells in a time-dependent manner .
|
-
- HY-146462
-
|
Apoptosis
ROS Kinase
|
Cancer
|
Anticancer agent 59 (compound 11) has inhibitory activity against kinds of cancer cell lines, especially in A549 with IC50 of 0.2 μM. Anticancer agent 59 induces apoptosis and an increase of Ca 2+ and ROS in cancer cells. Anticancer agent 59 significantly decreases mitochondrial membrane potential. Anticancer agent 59 can suppress tumor growth in A549 mouse xenograft model .
|
-
- HY-115960
-
|
Others
|
Cancer
|
Anticancer agent 35 (compound 10), a sulfonylurea derivative, is a potent anticancer agent. Anticancer agent 35 inhibits A549, A431, PACA2 cell growth with IC50s of 18.1 µg/mL, 4.0 µg/mL, 18.9 µg/mL, respectively .
|
-
- HY-146170
-
|
Reactive Oxygen Species
EGFR
Apoptosis
|
Cancer
|
Anticancer agent 69 (Compound 34), a potent and selective anticancer agent , potently and selectively inhibits human prostate cancer cell line PC3 (IC50=26 nM). Anticancer agent 69 increases ROS level, down-regulates EGFR and induces apoptosis .
|
-
- HY-149951
-
|
Others
|
Cancer
|
Anticancer agent 107(Compd 11jc) has significant antitumor activity and can be used as an anticancer agent in the study of pulmonary metastatic melanoma .
|
-
- HY-161051
-
|
NAMPT
DNA Alkylator/Crosslinker
|
Cancer
|
Anticancer agent 177 (Compound 11b) is a NAMPT inhibitor and DNA alkylating agent. Anticancer agent 177 has antitumor activity in vitro and in vivo .
|
-
- HY-162670
-
|
CDK
|
Cancer
|
Anticancer agent 238 (compound 5) is an anticancer agent with a notably strong binding affinity towards the CDK-5 enzyme. Anticancer agent 238 shows a strong efficacy agains HCT116 and MCF7 cells, with IC50 values of 13.46 µM and 16.43 µM, respectively .
|
-
- HY-141861
-
-
- HY-163112
-
|
Others
|
Cancer
|
Anticancer agent 179 (Compound 3) is a sambutoxin analogue. Anticancer agent 179 can impede migration of MDA-MB-231 breast cancer cells .
|
-
- HY-158049
-
|
Apoptosis
Ferroptosis
|
Cancer
|
Anticancer agent 199 (Compound G-4) induces apoptosis in triple negative breast cancer (TNBC) cells via the mitochondrial pathway through inhibiting EGFR, AKT and MAPK pathways. Anticancer agent 199 also induces Ferroptosis by down-regulating LCN2. Anticancer agent 199 inhibits TNBC cell viability and migration, and induces S phase cell cycle arrest. Anticancer agent 199 is a derivate of cyclin-dependent kinase inhibitor Rocovitine .
|
-
- HY-163770
-
|
Proteasome
|
Cancer
|
Anticancer agent 233 (compound 5g) is a 3,5-bis(arylmethylene)-4-piperidinone derivative with anticancer activity, with GI50 of 0.25 and 0.23 μM for cervical cancer (HeLa) and colon cancer (HCT116) cell lines, respectively. The chlorine atom on the aromatic ring of Anticancer agent 233 interacts well with the catalytic site of 20S proteasome, inhibiting the activity of 20S proteasome to exert its anticancer effect .
|
-
- HY-157487
-
|
Others
|
Cancer
|
Anticancer agent 185 (compound 9d) is a glycohybrid derivative of pyrazolopyrimidine [1,5-a]. Anticancer agent 185 has good anti-breast cancer activity. Anticancer agent 185 shows good cytotoxic activity against MCF-7 cells with IC50 value of 15.3 μM .
|
-
- HY-157931
-
|
Histamine Receptor
|
Neurological Disease
|
Anticancer agent 192 (compound XXI) is a steroid-based histamine H3 receptor antagonist with no affinity for muscarinics and hERG. Anticancer agent 192 is quite stable in human and rat liver microsomes. Anticancer agent 192 can improve the cognitive level and reduce the degree of addiction in rats in the in vivo addiction test .
|
-
- HY-146511
-
|
Others
|
Cancer
|
Anticancer agent 41 is a potent anticancer agent, shows a potent antitumor activity against MDA-MB-231 cell with an IC50 of 3.99 μM[1].
|
-
- HY-149343
-
|
Apoptosis
Autophagy
|
Cancer
|
Anticancer agent 132 (compound Rh1) is an inducer of apoptosis and autophagy with antitumor and antimetastasis activity. Anticancer agent 132 arrests cell cycle and inhibits cell proliferation .
|
-
- HY-162311
-
|
Ferroptosis
Autophagy
Reactive Oxygen Species
|
Cancer
|
Anticancer agent 194 (compound 10p) is a ferroptosis and autophagy inducer. Anticancer agent 194 arrests colon cancer cell cycle at G2/M phase, but can't induce cell apoptosis. Anticancer agent 194 independently triggeres cell ferroptosis and autophagy through the massive accumulation of ROS .
|
-
- HY-161661
-
|
Others
|
Cancer
|
Anticancer agent 223 (Compound V-d) is an anticancer agent that triggers cell death through caspase-dependent and caspase-independent mechanisms. Anticancer agent 223 inhibits tumor spheroid formation and resensitizes cisplatin (HY-17394)-resistant A2780 cells to cisplatin (HY-17394) treatment .
|
-
- HY-155146
-
|
Necroptosis
|
Cancer
|
Anticancer agent 146 (compound 1.19) is a necroptosis inducer. Anticancer agent 146 has anti-tumor efficacy in the mouse MDA-MB-231 xenograft model .
|
-
- HY-146452
-
|
Apoptosis
|
Cancer
|
Anticancer agent 57 (compound 14) potently inhibits MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC50s of 6.43 ~ 8.00 μM. Anticancer agent 57 induces cell cycle arrest and significantly promotes apoptosis. Anticancer agent 57 inhibits tumor growth in nude mice xenografted with MADMB-231 cells. Anticancer agent 57 can be used for researching triple negative breast cancer (TNBC) .
|
-
- HY-155203
-
|
Apoptosis
Reactive Oxygen Species
Ferroptosis
|
Cancer
|
Anticancer agent 154 (Compound 8h) increases the levels of reactive oxygen species and leads to mitochondrial damage. Anticancer agent 154 induces cell apoptosis and DNA damage. Anticancer agent 154 also induces ferroptosis by reducing the GSH level and GPX4 expression and increasing the lipid peroxidation level. Anticancer agent 154 inhibits cancer cell (HT29, H1975, A549, and MCF-7) proliferation with IC50s of 1.0-1.9 μM .
|
-
- HY-162751
-
|
HSP
Apoptosis
|
Cancer
|
Anticancer agent 249 (Compound 89) is an inhibitor for Hsp90β with IC50 of 16.5 μM in PC3MM2 cell. Anticancer agent 249 inhibits proliferation of cancer cells MCF-7, T47D, MDA-MB-231, MDA-MB-468 and SKBr3 with IC50 of 1.8-5.3 μM. Anticancer agent 249 induces apoptosis in MDA-MB-231. Anticancer agent 249 exhibits antitumor efficacy in mice .
|
-
- HY-115943
-
|
CDK
|
Cancer
|
Anticancer agent 30 (compound 6f-Z), a 3-arylidene-2-oxindole derivative, is a selective CDK2 inhibitor with potent anticancer activity .
|
-
- HY-115947
-
|
Others
|
Cancer
|
Anticancer agent 33 (compound 3), a Squamocin and Bullatacin derivative, is a potent anticancer agent. Anticancer agent 33 shows high potency to inhibit 4T1 breast cancer cell line (A549, HeLa, HepG2 and MCF-7 cells) growth with IC50s of 1.9-5.4 µM .
|
-
- HY-151207
-
|
Apoptosis
ADC Cytotoxin
|
Cancer
|
Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the antibody–agent conjugate (ADC) T-PBA. T-PBA maintained its mode of target and internalization ability of Trastuzumab .
|
-
- HY-155543
-
|
Androgen Receptor
|
Cancer
|
Anticancer agent 135 (compound 26h) is a potent androgen receptor (AR) antagonist. Anticancer agent 135 can effectively block AR nuclear translocation and inhibit AR/AR-V7 heterodimerization, thereby inhibiting downstream gene transcription. Anticancer agent 135 displays potent robust efficacy in prostate cancer xenograft models .
|
-
- HY-152084
-
|
Others
|
Cancer
|
Anticancer agent 93 is a 4-Hydroxycoumarin derivative. Anticancer agent 93 can inhibit invasion and migration of lung cancer cells by modulating expression of epithelial-mesenchymal transition (EMT) effectors .
|
-
- HY-152085
-
|
Others
|
Cancer
|
Anticancer agent 94 is a 4-Hydroxycoumarin derivative. Anticancer agent 94 can inhibit invasion and migration of lung cancer cells by modulating expression of epithelial-mesenchymal transition (EMT) effectors .
|
-
- HY-146461
-
|
Apoptosis
Caspase
ROS Kinase
|
Cancer
|
Anticancer agent 58 (compound 16) has inhibitory activity against kinds of cancer cell lines, especially in A549 and T24 with IC50s of 0.6 μM and 0.7 μM, respectively. Anticancer agent 58 induces apoptosis by activating caspase 3/8/9 activity, and induces an increase of Ca 2+ and ROS in cancer cells. Anticancer agent 58 significantly decreases mitochondrial membrane potential. Anticancer agent 58 can suppress tumor growth in T24 mouse xenograft model .
|
-
- HY-162688
-
|
Telomerase
G-quadruplex
Apoptosis
Ferroptosis
|
Others
|
Anticancer agent 239 (Compound 5) is a ligand of hTERT promoter G-quadruplex DNA structures (hTERT G4) (Kd = 1.1 μM), and downregulates hTERT expression. Anticancer agent 239 decreases telomerase activity, shortens telomere length, and induces DNA damage, acute cellular senescence, and apoptosis. Anticancer agent 239 causes mitochondrial dysfunction, disrupts iron metabolism and activates ferroptosis in cancer cells. Anticancer agent 239 inhibits tumor growth in MDA-MB-231 xenograft mouse model .
|
-
- HY-155524
-
|
Apoptosis
|
Cancer
|
Anticancer agent 134 (compound 6a) is a environment-sensitive fluorescent probe and an apoptosis inducer, making a distinction between the tumor and normal tissues. Anticancer agent 134 localizes to the nuclear bodies in tumor slices .
|
-
- HY-156186
-
|
Others
|
Cancer
|
Anticancer agent 160 (Compound 6) is a natural product derived from Parthenium hysterophorus. Anticancer agent 160 is cytotoxic to HCT-116 cells, IC50=5.0 μM .
|
-
- HY-158005
-
|
Apoptosis
|
Cancer
|
Anticancer agent 195 (Compound 10) is an inhibitor for ELF3-MED23 PPI with Ki of 0.68 μM. Anticancer agent 195 induces apoptosis and exhibits antitumor activity .
|
-
- HY-115980
-
|
Apoptosis
|
Cancer
|
Anticancer agent 39 (compound B12), a fluorescent derivative of Jiyuan Oridonin A (JOA), induces the collapse of mitochondrial membrane potential (MMP)and thus induced apoptosis.Anticancer agent 39 inhibits cell cloning and migration.Anticancer agent 39 exhibits promising anti-proliferative activity against HGC-27 cells with IC50 value of 0.39 μM .
|
-
- HY-149920
-
|
Microtubule/Tubulin
|
Cancer
|
Anticancer agent 98 (compound 12k) is a microtubule/tubulin-polymerization inhibitor (Kd=16.9 μM). Anticancer agent 98 exerts antiproliferative potency against tumor cells, exhibits anti-angiogenesis effect in vitro. Anticancer agent 98 exhibits good human and mouse liver microsomes stability with both t1/2>300 min .
|
-
- HY-108887
-
|
Raf
|
Cancer
|
Anticancer agent 124 is an orally active, highly selective and potent pan RAF inhibitor. Anticancer agent 124 inhibits MAPK signalling in BRAF V600E, NRAS and KRAS mutant tumor cells .
|
-
- HY-157876
-
|
P-glycoprotein
BCRP
|
Cancer
|
Anticancer agent 191 (Compound 2) is a derivative of probenecid (HY-B0545). As a cancer cell efflux inhibitor, Anticancer agent 191 is designed to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and/or multiple multidrug resistance proteins (MRPs). Anticancer agent 191 increases the accumulation of vinblastine in cancer cells, which is used for cancer research .
|
-
- HY-W072940
-
|
FOXO
Phosphatase
|
Cancer
|
Anticancer agent 7 (Example 5) modulates PP2A, and induces FOXOl transcription factor translocation to the nucleus. Anticancer agent 7 inhibits the proliferation of H1650 lung cancer cell with an IC50 of 5 μM .
|
-
- HY-156607
-
|
Phosphatase
|
Cancer
|
Anticancer agent 143 (compound 369) is a dual PTPN2/PTP1B inhibitor with IC50 values <2.5 nM. Anticancer agent 143 can be used in cancer research .
|
-
- HY-156608
-
|
Phosphatase
|
Cancer
|
Anticancer agent 144 (compound 444) is a dual PTPN2/PTP1B inhibitor with IC50 values <2.5 nM. Anticancer agent 144 can be used in cancer research .
|
-
- HY-146105
-
|
Apoptosis
MDM-2/p53
MMP
Bcl-2 Family
Reactive Oxygen Species
|
Cancer
|
Anticancer agent 65 (compound 4c) shows excellent activity in cancer cell lines, especially A549 cells, with an IC50 of 1.07 μM. Anticancer agent 65 induces S-phase arrest in A549 cells and increases the expression level of p53 and p21. Anticancer agent 65 causes apoptosis, ROS generation and collapse of MMP in A549 cells .
|
-
- HY-155158
-
|
Ferroptosis
|
Cancer
|
Anticancer agent 147 (compound 6j) is a derivative of sophoridine (HY-N1373) and is a ferroptosis inducer. Anticancer agent 147 can promote the accumulation of intracellular Fe2+, reactive oxygen species (ROS) and MDA, increase ER stress, and upregulate the expression of the activating transcription factor ATF3. Anticancer agent 147 has good anti-liver cancer effects in vitro and in vivo .
|
-
- HY-163629
-
|
Others
|
Cancer
|
Anticancer agent 224 (Compound 16) is an anticancer agent that can effectively inhibit the growth of central nervous system (CNS), kidney and breast cancer cell, with a GI50 value ranging from 0.6 to 12.8 μM .
|
-
- HY-163435
-
|
Apoptosis
Caspase
PARP
Bcl-2 Family
|
Cancer
|
Anticancer agent 201 (Compound 2f) has IC50 values in the low micromolar range for multiple tumor cell lines. Anticancer agent 201 is highly cytotoxic to CCRF-CEM cells in vitro, inducing apotosis by activating caspase-3 in the intrinsic mitochondrial pathway and lysis of PARP, as well as reducing the expression of Bcl-2 and Bcl-XL proteins. Anticancer agent 201 can be used in cancer research .
|
-
- HY-139252
-
|
Reactive Oxygen Species
|
Cancer
|
Anticancer agent 225 (Comp 51) is a triterpenoic acids analogue which exhibits suppressive effect on elimination of different type of cancer stem cells (CSCs) and increase the ROS level of CSCs. Anticancer agent 225 can be used for cancer research .
|
-
- HY-149523
-
|
Apoptosis
NO Synthase
Caspase
|
Inflammation/Immunology
Cancer
|
Anticancer agent 157 (compound 15) is a NO inhibitor (IC50=0.62 μg/mL) with anti-inflammatory and anticancer activities. Anticancer agent 157 can bind to iNOS (inducible NO synthase) and caspase 8, causing nuclear fragmentation and chromatin condensation, inducing apoptosis. Anticancer agent 157 inhibits HT29 colon cancer cells (IC50=2.45 μg/mL), Hep-G2 liver cancer cells (IC50=3.25 μg/mL), and B16-F10 murine melanoma cells (IC50=3.84 μg/mL) .
|
-
- HY-151120
-
|
Others
|
Cancer
|
Anticancer agent 79 (compound 3d) shows good anti-breast cancer activity. Anticancer agent 79 shows good cytotoxic activity in T47-D cells, with an IC50 of 13.64 ± 0.26 μM .
|
-
- HY-162310
-
|
Ferroptosis
Reactive Oxygen Species
Autophagy
|
Cancer
|
Anticancer agent 193 (compound D3-3) is an inducer of ferritinophagy, eventually triggering ferroptosis. Anticancer agent 193 induces the production of lipid ROS, and significantly promoted colorectal cancer cells to release the ferrous ion in an autophagy-dependent manner .
|
-
- HY-158019
-
|
DNA/RNA Synthesis
|
Cancer
|
Anticancer agent 196 (compound 1) shows cell cytotoxicity with IC50 values of 7.69 µM and 54.2 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 196 can induce DNA damage .
|
-
- HY-170527
-
|
Reactive Oxygen Species
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Anticancer agent 260 (Compound 3g/4d) is an orally active anticancer agent, that inhibits the proliferation of cancer cell HCT-116, MIA-PaCa2 and MDA-MB231 with IC50s of 98.7, 81.0, and 77.2 µg/mL, respectively. Anticancer agent 260 exhibits promotes ulcer formation and lipid peroxidation, anti-inflammatory and analgesic efficacy .
|
-
- HY-158020
-
|
DNA/RNA Synthesis
|
Cancer
|
Anticancer agent 197 (compound 2b) shows cell cytotoxicity with IC50 values of 10.03 µM and 73.54 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 197 can induce DNA damage .
|
-
- HY-144227
-
|
Others
|
Cancer
|
Anticancer agent 27 deserves further development as a promising candidate for the research of cancer.
|
-
- HY-144225
-
|
Others
|
Cancer
|
Anticancer agent 26 deserves further development as a promising candidate for the research of cancer.
|
-
- HY-151588
-
|
Virus Protease
|
Cancer
|
Anticancer agent 90 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity. Anticancer agent 90 has high inhibition against the two cell line from ovarian cancer (OVCAR-4), renal cancer (A498) .
|
-
- HY-151592
-
|
Antibiotic
|
Cancer
|
Anticancer agent 91 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor and antiviral activity. Anticancer agent 91 has high inhibition against the two cell line from CNS cancer (SF-539 and SNB-75) .
|
-
- HY-149367
-
|
Apoptosis
|
Cancer
|
Anticancer agent 136 (compound 22), a C17-triazole analogue of Geldanamycin (GDM; HY-15230), has an IC50 of 3.38 μM for HDF and a Kd of 3.86 μM for Hsp90. Anticancer agent 136 is an apoptosis-inducing agent .
|
-
- HY-163077
-
|
Reactive Oxygen Species
Apoptosis
|
Cancer
|
Anticancer agent 175 (complex 1) ia a near-infrared (NIR) luminescent theranostic complex. Anticancer agent 175 induces ROS accumulation, mitochondrial damage, disruption of Bax/Bcl-2 equilibrium, and tumor cell apoptosis in HepG2 cell line .
|
-
- HY-163113
-
|
Others
|
Cancer
|
Anticancer agent 180 (compound 4) is a secondary metabolite present in fungal strains and extracted through physical interaction with Streptomyces sp. Anticancer agent 180 has potential anti-tumor activity and can inhibit the migration of MDA-MB-231 breast cancer cells .
|
-
- HY-156606
-
|
Phosphatase
|
Cancer
|
Anticancer agent 142 (compound 235) is a PTPN inhibitor, with the potential to study cancer .
|
-
- HY-115942
-
|
CDK
|
Cancer
|
Anticancer agent 29 (Compd E/Z-6f) is an anticancer agent, with IC50 values of 0.054 μM, 0.127 μM, 0.129 μM, 0.396 μM for CDK2, CDK1, CDK4 and CDK6, respectively .
|
-
- HY-149240
-
|
P-glycoprotein
|
Cancer
|
Anticancer agent 108 (Compound 3.10) is a potent P-gp inhibitor with significant antitumor activity and less toxicity to normal and pseudonormal cells. Anticancer agent 108 (Compound 3.10) had no acute toxic effect on С57BL/6 mice .
|
-
- HY-139705
-
|
Others
|
Cancer
|
Anticancer agent 12 is unexpectedly devoids of hepatotoxicity while maintaining cytotoxic activity in malignant cells.
|
-
- HY-156097
-
|
EGFR
|
Cancer
|
Anticancer agent 158 (compound 7c) is a potent anticancer agent. The IC50s for inhibiting HepG-2, MDA-MB-231, and HCT-116 cell lines are 7.93 μM, 9.28 μM, 13.28 μM, and 181.89 μM, respectively .
|
-
- HY-151565
-
|
Others
|
Cancer
|
Anticancer agent 86 (compound 6i) shows potential activity against breast adenocarcinoma .
|
-
- HY-155019
-
|
IAP
|
Cancer
|
Anticancer agent 128 (compound 1) is an IAP inhibitor that covalently targets the BIR3 domains of XIAP, cIAP1, and cIAP2. Anticancer agent 128 targets the BIR3 domains of XIAP, cIAP1, and cIAP2 with IC50s of 24.9 nM, 19.3 nM, and 10.3 nM, respectively .
|
-
- HY-164320
-
|
Others
|
Cancer
|
Anticancer agent 245 (Compound 115) inhibits proliferation of cancer cell SKOV3, MDA-MB-231 and HCT-116 with IC50 of 0.021, 0.056 and 0.11 μM, respectively. Anticancer agent 245 exhibits antitumor efficacy in mice and good pharmacokinetic characteristics in rat models .
|
-
- HY-147504
-
|
Apoptosis
Caspase
Bcl-2 Family
|
Cancer
|
Anticancer agent 63 (compound 3h) shows active in reducing the viability of different cancer cell lines, including SW480, HeLa, A549 and MCF-7, with IC50 values at 24 h of 4.9, 11.5, 9.4, and 3.4 μM, respectively. Anticancer agent 63 induce apoptosis in MCF-7 cells via down-regulating the expression of Bcl-2 and up-regulating the expression of IL-2 and Caspase-3. Anticancer agent 63 also shows antioxidant activity .
|
-
- HY-161755
-
|
Endogenous Metabolite
|
Cancer
|
Anticancer agent 232 (compound 12f) is a glycohybrid designed using 1-azidoglycosides derived from d-glucose, d-galactose, and d-mannose. The IC50 values of anticancer agent 232 against MCF-7 and MDA-MB231 cells are 1.05 μM and 18.03 μM, respectively .
|
-
- HY-143641
-
|
Others
|
Cancer
|
Anticancer agent 25 exhibits the strongest cytotoxicity against PC3 cells with an IC50 value of 0.19 μM.
|
-
- HY-161845
-
|
Others
|
Cancer
|
Anticancer agent 240 (compound 9b) is an 8-quinolinesulfonamide derivative with a cytotoxicity activity. Anticancer agent 240 shows inhibitory activity in Caco-2, SNB-19, A-549, and SKOV-3 cell line IC50 values of 0.26, 0.38, 0.40 and 4.16 μM .
|
-
- HY-117782
-
|
Others
|
Cancer
|
Anticancer agent 236 (compound JP-8g) is a broad-spectrum anticancer agent that has toxic effects on several cancer cell lines with IC50 values of 6.925 μM (MDA), 6.296 μM (U937), 6.548 μM (Jurkat), 6.373 μM (Hela), and 10.381 μM (EJ) .
|
-
- HY-139860
-
|
Reactive Oxygen Species
|
Cancer
|
Anticancer agent 15 is capable of significantly increasing the cellular level of ROS and inducing melanoma cancer cell death via necroptosis.
|
-
- HY-162575
-
|
ERK
|
Cancer
|
Anticancer agent 231 (Compound P5) is a tyrosine protein kinase inhibitor with a IC50 value of 3.95 μM. Anticancer agent 231 inhibits the cell viability, cell proliferation, cell migration and cancer dryness of triple negative breast cancer (TNBC) cells by targeting EGFR-ERK 1/2 signaling pathway, and is expected to play an important role in the field of TNBC disease therapy .
|
-
- HY-129909
-
|
Apoptosis
|
Infection
Cancer
|
Anticancer agent 173 (compound 19) is a potent thioxodihydroquinazolinone analogs when combined with platinum drugs in inducing apoptotic cancer cells death .
|
-
- HY-162292
-
|
PI3K
Kinesin
|
Cancer
|
Anticancer agent 190 (compound 3e) is an inhibitor targeting KSP (Kinesin) and PI3Kδ with activity against breast cancer .
|
-
- HY-141649
-
-
- HY-149997
-
-
- HY-154862
-
|
Apoptosis
|
Infection
Cancer
|
Anticancer agent 119 (compound 15) is an N-acylated ciprofloxacin derivative, which has certain antibacterial activity and induces ROS production to promote cancer cell apoptosis .
|
-
- HY-139828
-
|
Apoptosis
|
Cancer
|
Anticancer agent 14 is a lead compound (IC50: 0.20 to 0.65 μM) that induces apoptosis, cell cycle arrest, and loss of mitochondrial membrane potential in breast cancer cells.
|
-
- HY-158388
-
|
Topoisomerase
|
Cancer
|
Anticancer agent 215 (1) is a Camptothecin compound, with IC50 values of 5.2 nM and 8.2 nM in MCF-7 cells and MDA-MB-231 cells, respectively .
|
-
- HY-158389
-
|
Topoisomerase
|
Cancer
|
Anticancer agent 216 (34A) is a Camptothecin compound, with IC50 values of 9.6 nM and 11.6 nM in MCF-7 cells and MDA-MB-231 cells, respectively .
|
-
- HY-158387
-
|
Topoisomerase
|
Cancer
|
Anticancer agent 214 (2) is a Camptothecin compound, with IC50 values of 2.6 nM and 15.7 nM in MCF-7 cells and MDA-MB-231 cells, respectively .
|
-
- HY-N13063
-
|
Apoptosis
Reactive Oxygen Species
PI3K
Akt
|
Cancer
|
Anticancer agent 235 (Compound 49) is a modulator for PI3K/AKT/mTOR pathway, that promotes the generation of ROS, reduces the mitochondrial membrane potential, and thereby inhibits the proliferation of cancer cells HCT116, Caco-2, AGS and SMMC-772 with IC50 of 0.35-26.9 μM. Anticancer agent 235 arrests the cell cycle at G2/M phase, and induces apoptosis in HCT116 .
|
-
- HY-162721
-
|
Others
|
Cancer
|
Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC50 = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC50 = 0.45 μM, resistant derivative of A2780), CCD18Co (IC50 = 0.59 μM, non-malignant human fibroblasts), A549 (IC50 = 0.32 μM, lung carcinoma), HT29 (IC50 = 0.26 μM, colorectal adenocarcinoma), and MCF7 (IC50 = 0.55 μM, breast adenocarcinoma) .
|
-
- HY-158390
-
|
Topoisomerase
|
Cancer
|
Anticancer agent 217 (35B) is a Camptothecin compound, with IC50 values of 6.2 nM and 7.1 nM in MCF-7 cells and MDA-MB-231 cells, respectively .
|
-
- HY-162752
-
|
Apoptosis
|
Cancer
|
Anticancer agent 250 (compound 104) has antitumor activity, inducing apoptosis, slowing proliferation, and degrading key oncogenic proteins (such as aRaf, CDK4 ) without inducing a heat shock response .
|
-
- HY-119324
-
|
Others
|
Others
|
Anticancer agent 254 (compound 10) is a dichloroacetic acid-loaded compound with enhanced antitumor activity against leukemia cells in vitro and better stability in vivo, and can be considered for preclinical evaluation of cancer inhibition.
|
-
- HY-149327
-
|
Others
|
Cancer
|
HCT-116-IN-1, a γ-lactam-fused pyridone derivative, has anticancer activity and displayed high cytotoxicity against HCT116 cells with an IC50 of 5.59 μM .
|
-
- HY-146465
-
|
Microtubule/Tubulin
|
Cancer
|
Anticancer agent 60 (compound 3h) has antiproliferative activity against human HepG2 cells (IC50 = 4.13 μM) and presents antitumor efficacy in a human HepG2 xenograft mouse model .
|
-
- HY-144232
-
|
Others
|
Cancer
|
Anticancer agent 28 showed good antitumor activity in H22 allogeneic mice in vivo. Its potency in K562 cells was 50 times that of oridonin, and its < b > IC < sub > 50 < / sub > < / b > value was 0.09 μ M。
|
-
- HY-139882
-
|
Others
|
Cancer
|
Anticancer agent 16 exhibits good cytotoxic activity against HCT-116, NCI-H460, and SKOV3 cell lines with IC50 8.55 μΜ, 5.41 μΜ, and 6.4 μΜ, respectively.
|
-
- HY-168730
-
|
STAT
|
Cancer
|
Anticancer agent 259 (Compound 3g) is a Telmisartan (HY-13955)-based cell death modulator, that interfers with the STAT5 signaling pathway, enhances the sensitivity of drug-resistant cells to Imatinib (HY-15463) with SC50 of 1.5 μM .
|
-
- HY-151587
-
|
Others
|
Cancer
|
Anticancer agent 89 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity, has high inhibition against the three cell line from ovarian cancer (OVCAR-4), renal cancer (A498), and melanoma (SK-MEL-5) .
|
-
- HY-128634
-
|
Apoptosis
PI3K
MEK
|
Cancer
|
CML-IN-1 (compound 7) is a potent anticancer agent. CML-IN-1 displays very good induced-apoptosis effect for human chronic myeloid leukemia (CML) cell line K562. CML-IN-1 exerts its effect via a significantly reduced protein phosphorylation of PI3K/Akt signal pathway. CML-IN-1 (compound 4) also inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer .
|
-
- HY-160263S
-
-
- HY-N7669
-
-
- HY-19188
-
|
Apoptosis
|
Cancer
|
GL-331 is a potent anti-cancer agent. GL-331 has demonstrated more efficacious anti-cancer activity in both the in vitro and in vivo lymphoma systems .
|
-
- HY-W092549
-
-
- HY-16941
-
|
Others
|
Cancer
|
Damulin A is a saponin found in G. pentaphyllum with anti-cancer activities .
|
-
- HY-N10346
-
|
Endogenous Metabolite
|
Cancer
|
Gluconapin potassium is the precursor of sulforaphane. Sulforaphane is a potent anti-cancer isothiocyanate .
|
-
- HY-153757
-
|
Others
|
Cancer
|
Antioxidant agent-11 (compound 3d) is a compound that has weak anti-cancer and antioxidant activities .
|
-
- HY-145717
-
|
Others
|
Cancer
|
Deoliosyl-3C-α-L-digitoxosyl-MTM, a compound, shows decreased anti-cancer activity compared to mithramycin .
|
-
- HY-155953
-
|
Others
|
Cancer
|
6-epi-COTC is a diastereoisomer of Streptomyces metabolite with a anti-cancer activitie .
|
-
- HY-116518
-
|
Others
|
Cancer
|
Piperafizine A (compound 4d’) is a N-monoalkylated plinabulin derivative. Anti-cancer reagent .
|
-
- HY-135848
-
|
Phosphodiesterase (PDE)
|
Cancer
|
N-Methylbenzamide is a potent phosphodiesterase 10A (PDE10A) inhibitor. N-Methylbenzamide has anti-cancer activity .
|
-
- HY-123786
-
|
Others
|
Cancer
|
NSC745887 (compound 25) is an anti-cancer agent. NSC745887 exhibits dose-dependent inhibition of proliferation in all 60 cancer cell lines .
|
-
- HY-30236
-
|
Drug Intermediate
|
Cancer
|
5-Bromoindole is a chemical intermediate that can be used for the synthesis of GSK-3 inhibitors and anti-cancer agents .
|
-
- HY-12538
-
Rutamine
|
Apoptosis
Autophagy
Fungal
|
Infection
Cancer
|
Graveoline (Rutamine) is an anti-cancer agent that can trigger apoptosis and autophagy in skin melanoma cells. Graveoline also exhibits antifungal activity .
|
-
- HY-W012732
-
|
Drug Isomer
|
Cancer
|
Isoquinoline is an analog of pyridine. Isoquinoline structural-based alkaloids, such as tropoloisoquinoline, phthalideisoquinoline, and naphthylisoquinoline has anti-cancer activities .
|
-
- HY-136526
-
|
Bcr-Abl
|
Cancer
|
BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC50 of ≤100 nM for Ba/F3Bcr-Abl T3151. BCR-ABL-IN-3 has anti-cancer activity .
|
-
- HY-N2181A
-
|
Cytochrome P450
|
Inflammation/Immunology
Cancer
|
DL-Acetylshikonin is a non-selective, reversible cytochrome P450 inhibitor with IC50 values of 1.4-4.0 μM. DL-Acetylshikonin has anti-cancer and anti-inflammatory activities .
|
-
- HY-110172
-
|
PDI
|
Cancer
|
PDI-IN-1 (Compound P1) is a cell-permeable human protein disulfide isomerase (PDI) inhibitor with an IC50 of 1.7 μM. PDI-IN-1 has anti-cancer activity.
|
-
- HY-120936
-
|
DNA/RNA Synthesis
|
Cancer
|
IACS-4759 is a potent and selective MTH1 (MutT homolog 1) inhibitor with an IC50 of 0.6 nM. IACS-4759 has anti-cancer effects .
|
-
- HY-147776
-
|
MDM-2/p53
|
Cancer
|
Antiproliferative agent-8 (Compound 5a) is an anti-cancer agent. Antiproliferative against-8 has antiproliferative activity. Antiproliferative agent-8 significantly increases the P53 levels .
|
-
- HY-N1217
-
Stauntoside C
|
Na+/K+ ATPase
|
Cancer
|
Stauntosaponin A, a steroid glycoside, is a potent inhibitor of Na(+)/K(+)-ATPase with an IC50 value of 21 nM. Stauntosaponin A can be isolated from Carnation and has potential anti-cancer research value .
|
-
- HY-N7288
-
|
Others
|
Others
|
Trilepisflavan is a flavan, which can be isolated from Trilepisium madagascariense. Trilepisflavan derivates serval analogues with anti-cancer activity against human cancer cells .
|
-
- HY-120313
-
|
Others
|
Cancer
|
SN23862 is a cancer prodrug with anti-cancer activity, and an analogue of CB-1954 (HY-13543). SN23862 can be used for cancer research .
|
-
- HY-N4252
-
|
Others
|
Cancer
|
Periplocymarin, a cardiac glycoside isolated from Periploca sepium and Periploca graeca, is a potential anti-cancer compound .
|
-
- HY-W015084A
-
β-Lonone
|
Apoptosis
|
Cancer
|
(E)-β-Ionone is the isomer of β-Ionone (HY-W015084). β-Ionone is effective in the induction of apoptosis in gastric adenocarcinoma SGC7901 cells. β-Ionone has anti-cancer activity .
|
-
- HY-136204
-
-
- HY-19118
-
FFC14A
|
Apoptosis
|
Cancer
|
KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells .
|
-
- HY-N6637
-
|
Others
|
Cancer
|
Senecionine n-oxide is the primary product of pyrrolizidine alkaloid biosynthesis in root cultures of Senecio vulgaris. Senecionine N-oxide has anti-cancer activity .
|
-
- HY-P99517
-
JNJ-63898081
|
CD3
|
Cancer
|
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .
|
-
- HY-130607
-
-
- HY-136203
-
-
- HY-15044
-
|
PARP
|
Neurological Disease
Cancer
|
NU1025 is a potent PARP inhibitor with an IC50 of 400 nM and a Ki of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer agents. NU1025 has anti-cancer and neuroprotective activity .
|
-
- HY-13777
-
Zoledronate; CGP 42446; CGP42446A; ZOL 446
|
Apoptosis
Autophagy
Bacterial
|
Metabolic Disease
Cancer
|
Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .
|
-
- HY-13777A
-
Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate
|
Apoptosis
Autophagy
Bacterial
|
Metabolic Disease
Cancer
|
Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects .
|
-
- HY-16942
-
|
Apoptosis
|
Cancer
|
Damulin B is a dammarane-type saponin found in Gynostemma pentaphyllum.Damulin B can induce cell apoptosis and has anti-cancer activities in vitro .
|
-
- HY-N2423
-